TAKE Limited Reports H1 FY27 Consolidated Income of ₹61.55 Cr, Returns to Profitability
TAKE Limited reported H1 FY27 consolidated income of ₹61.55 crore and PAT of ₹3.28 crore, returning to profitability. Q2 FY27 consolidated net profit grew 108% QoQ to ₹2.21 crore. The company launched TAKE.Health, a ₹5 crore Innovation Fund, and entered the longevity market.
The return to profitability, coupled with substantial investments in innovation and strategic market entries, indicates a significant positive shift in the company's financial and business trajectory.
The company has returned to profitability and shown significant quarter-on-quarter growth in net profit, alongside strategic initiatives and investments in future growth areas.
TAKE Limited announced its financial results for the half year ended September 30, 2026, reporting a consolidated Total Income of ₹615.54 Million (₹61.55 crore). The company achieved a consolidated Profit After Tax (PAT) of ₹32.75 Million (₹3.28 crore) for H1 FY27, a significant turnaround from a loss of ₹12.13 Million (₹1.21 crore) in H1 FY26.
On a standalone basis, Total Income for the half year ended September 2026 stood at ₹280.52 Million (₹28.05 crore), with Net Profit reaching ₹31.89 Million (₹3.19 crore), compared to a loss in the prior year. For the second quarter of FY27 (Q2 FY27), consolidated Total Income was ₹298.52 Million (₹29.85 crore), and consolidated Net Profit rose to ₹22.12 Million (₹2.21 crore), an increase of 108.17% quarter-on-quarter. Standalone Net Profit for Q2 FY27 grew to ₹22.21 Million (₹2.22 crore), a 129.36% increase from the previous quarter.
Alongside financial recovery, TAKE Limited is advancing its strategic vision in digital healthcare, AI, and longevity sciences. Key initiatives include the launch of TAKE.Health, an intelligent digital health companion, and a ₹50 Million (₹5 crore) Innovation Fund to support startups in AI, deep technology, and digital health. The company also announced its strategic entry into India's longevity and anti-ageing market, planning to develop science-backed nutraceuticals and preventive healthcare solutions.
Looking ahead, TAKE Limited will focus on strengthening its presence in digital healthcare, preventive wellness, and longevity sciences. Future priorities include enhancing TAKE.Health, developing longevity offerings, evaluating investment opportunities through the Innovation Fund, and applying AI across healthcare and life sciences, all while maintaining financial discipline and focusing on commercially viable offerings.
Mr. Sunil Patra, Managing Director of TAKE Limited, stated, "Our return to profitability... is an encouraging development. We are particularly focused on the convergence of healthcare, science and technology. Initiatives such as TAKE.Health, our Innovation Fund and our strategic entry into the longevity and preventive healthcare segment reflect our ambition to develop businesses that address evolving healthcare needs through innovation and technology."
What to do with a filing like this
TAKE Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by TAKE Limited. Read the original for the full detail.